Article
Daclatasvir plus asunaprevir dual therapy for chronic HCV genotype 1b infection: results of Turkish early access program.
Annals of hepatology - 1 Jan 2000
Köklü Seyfettin, Köksal Iftihar, Akarca Ulus Salih, Balkan Ayhan, Güner Rahmet, Demirezen Aylin, Sahin Memduh, Akhan Sila, Ozaras Reşat, Idilman Ramazan
Abstract excerpt
Background. Daclatasvir and asunaprevir dual therapy is approved for the treatment of HCV genotype 1b infection in several countries. AIM: To evaluate the efficacy and safety of daclatasvir and asunaprevir dual therapy in Turkish patients. MATERIAL AND METHODS: Sixty-one patients with HCV genotype 1b were enrolled in the Turkish early access program. Most of the patients were in difficult-to-treat category....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.